|Min SIP Amount||₹500|
|NAV||₹85.25 (13 Sep 2019)|
|Fund Started||01 Jan 2013|
|Fund Size||₹384 Cr|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||12.0%|
|Divi's Laboratories Ltd.||Healthcare||Equity||9.3%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||7.3%|
|Ipca Laboratories Ltd.||Healthcare||Equity||6.0%|
|Cadila Healthcare Ltd.||Healthcare||Equity||6.0%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||4.9%|
|Sanofi India Ltd.||Healthcare||Equity||4.8%|
|Torrent Pharmaceuticals Ltd.||Healthcare||Equity||3.3%|
UTI Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was introduced to investors on 01 Jan 2013. V Srivatsa, Ritesh Rathod is the Current Fund Manager of UTI Healthcare Fund Direct Growth.The fund currently has an Asset Under Management(AUM) of ₹384 Cr and the Latest NAV as of 13 Sep 2019 is ₹85.25.
The UTI Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is 500. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed less than 1 year.
1st Floor, Proms Complex, SBI
Colony, 1A Koramangala, 560034